Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

157.53 -0.80 (-0.50%)

Delayed Quote Updated: 11:21 AM EDT, Oct 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,155,010
Open	160.76
Bid (Size)	157.51 (100)
Ask (Size)	157.56 (100)
Prev. Close	158.33
Today's Range	157.40 - 160.83
52wk Range	153.41 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.59%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗

October 12, 2026

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research...

Via MarketBeat

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Via The Motley Fool

Performance

52-Week Range 25.9% below 52-week high

157.53

153.4152W Low 212.7152W High

1 Week 2.3% below 1-week high

156.261W Low 161.291W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $153.41 and $212.71 over the past 52 weeks and last traded at $157.53, 25.9% below its 52-week high. Over the past week it ranged between $156.26 and $161.29.

Past 12 Months

-0.7%

-3.8%

-7.0%

-22.1%

-16.4%

1W -$1.08

1M -$6.25

3M -$11.94

6M -$44.71

YTD -$30.88

1Y -$30.88

AZN was -16.4% over the past year, -22.1% over six months, -16.4% year to date, -0.7% in the last week.

12 Months vs Market

AZN

-16.4%

DIA

+12.3%

SPY

+17.2%

QQQ

+23.2%

IWM

+13.1%

Over the past 12 months AZN returned -16.4% versus DIA (Dow) +12.3%, SPY (S&P 500) +17.2%, QQQ (Nasdaq 100) +23.2% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 0.35× 3-mo avg

Today 1,155,010 3-mo avg 3.3M

2.6M

2.8M

3.3M

2.7M

YTD

2.6M

AZN most recently traded 1,155,010 shares against a 3-month average daily volume of 3.3M.

More News

2 Growth Stocks to Buy in October ↗

October 08, 2026

Via The Motley Fool

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

October 05, 2026

From AstraZeneca

Via Business Wire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Via The Motley Fool

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

From AstraZeneca

Via Business Wire

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Via The Motley Fool

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

September 13, 2026

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026

From AstraZeneca

Via Business Wire

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗

September 13, 2026

Via MarketBeat

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

September 08, 2026

From AstraZeneca

Via Business Wire

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 08, 2026

From AstraZeneca

Via Business Wire

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 04, 2026

From AstraZeneca

Via Business Wire

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

Via The Motley Fool

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

September 01, 2026

From AstraZeneca

Via Business Wire

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Via The Motley Fool

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

August 27, 2026

From AstraZeneca

Via Business Wire

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

From MarketNewsUpdates.com

Via GlobeNewswire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

From USA News Group

Via GlobeNewswire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

August 17, 2026

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

August 17, 2026

From AstraZeneca

Via Business Wire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Via The Motley Fool

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 157.53

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 10/13/26 11:21 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.